Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests and speech analysis could spot dementia sooner

NCT ID NCT07842029

Diagnosis Sponsor: Prima Mente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Memory Clinic waits can delay dementia care. This study tests whether giving clinicians extra test results helps them diagnose dementia earlier. Adults aged 50 and over referred by their GP complete a blood test for two Alzheimer's-related proteins, a genetic test for the APOE gene, and a memory and thinking assessment that includes a recorded speech task. Researchers share all results with the participant's clinician and track how the approach affects wait times, clinician satisfaction, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a diagnostic approach combining a blood biomarker test, an APOE genetic test, and a recorded speech and memory assessment
What this could lead to
If it works, this approach could help Memory Clinic clinicians diagnose dementia earlier, so patients get care and treatment sooner.
What could go wrong
The study measures whether the approach is usable and acceptable, not whether it improves outcomes. Earlier diagnosis may not change the course of disease, and the tests are not yet standard on the NHS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 50 years or older with subjective or objective cognitive impairment who have been referred to Memory Clinics for diagnostic clarification. Participants are recruited from Memory Clinic waiting lists across multiple NHS sites in England and Wales and are awaiting secondary care assessment for memory concerns. The study population includes individuals experiencing cognitive difficulties but without a prior dementia diagnosis.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant is willing and able to provide informed consent for participation in the study, or if unable to consent, a consultee (nearest of kin or holder of Power of Attorney) is available to make a declaration. * Eligibility for recruitment in Scotland is restricted to participants who are able to provide informed consent themselves; participants requiring consultee consent will not be recruited in Scotland. * Male or female, aged 50 years or older. * The participant is currently on a waiting list for a participating Memory Clinic. * The participant lives within traveling distance to a study site. * The participant agrees to complete all study procedures, including genetic testing. Exclusion Criteria: * The participant may not enter the study if any of the following criteria apply: * The participant has known or anticipated challenges with venous blood sampling. * The participant is not fluent in English. * The participant has a historical diagnosis of dementia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia Nerve Degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive impairment Dementia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    11 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aneurin Bevan University Health Board Clinical Research Centre

    RECRUITING

    Newport, Wales, NP20 2UB, United Kingdom

  • Berkshire Healthcare NHS Foundation Trust

    RECRUITING

    Reading, RG6 7BE, United Kingdom

    Contact Email: •••••@•••••

  • Bradford District Care Foundation Trust

    RECRUITING

    Bradford, BD9 6DP, United Kingdom

  • Cardiff and Vale University Health Board

    RECRUITING

    Penarth, CF64 2XX, United Kingdom

  • Central and North West London NHS Foundation Trust

    RECRUITING

    London, London, NW5 3EG, United Kingdom

  • Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust

    RECRUITING

    Newcastle upon Tyne, NE4 5PL, United Kingdom

  • Cwm Taf Morgannwg University Health Board

    RECRUITING

    Bridgend, CF31 1RQ, United Kingdom

  • Hywel Dda University Health Board

    ACTIVE_NOT_RECRUITING

    Llanelli, SA148QF, United Kingdom

  • Imperial College Healthcare NHS Trust

    RECRUITING

    London, Greater London, W6 8RF, United Kingdom

  • Surrey and Borders Partnership NHS Foundation Trust

    RECRUITING

    London, Surrey, KT22 7AD, United Kingdom

  • Swansea Bay University Health Board

    RECRUITING

    Swansea, SA2 8PP, United Kingdom

  • West London NHS Trust

    RECRUITING

    London, London, UB1 3HW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.